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Abstract  
Background Current clinical guidelines recommend that risk stratification for ischaemic stroke in patients with 
nonvalvular AF (NVAF) should be performed using the CHA2DS2-VASc score (Congestive heart failure, 
Hypertension, Age ≥ 75 years [double], Diabetes mellitus, previous thromboembolism [double], Vascular disease, 
Age 65-74 years, and female gender) to aid decision making for antithrombotic treatment, with a preference for 
Non-Vitamin K Oral Anticoagulants (NOACs) in those with CHA2DS2-VASc score ≥1. However, CHA2DS2-VASc score 
is not recommended in the 2014 Japanese Circulation Society (JCS) guidelines for patients with NVAF.  
Methods To assess the impact of the JCS approach to stroke prevention in AF, and model the impact of using 
a CHA2DS2-VASc based 2-step decision making strategy, we calculated the incidence of ischaemic stroke in NVAF 
patients without OAC on basis of the CHADS2 and CHA2DS2-VASc scores using published Japanese data, and 
estimated the preventable number of stroke events.  
Results  Using a CHA2DS2-VASc-based approach, the potential annual stroke events based on the estimated 
total number of NVAF patients in Japan was 889000, as follows: 4369 for dabigatran 150mg, 6049 for dabigatran 
110mg, 5918 for rivaroxaban (intention-to-treat; ITT), 5302 for apixaban, 5843 for edoxaban 60mg (ITT), 7598 for 
edoxaban 30mg (ITT), respectively.  Using a CHADS2 score-based approach, the number of potential stroke events 
was much greater for each agent. 
Conclusion Our modelling analysis has shown that when considering antithrombotic treatment for Japanese NVAF 
patients, using a CHA2DS2-VASc-based approach would allow greater opportunities for stroke prevention. 
 
Keywords     Dabigatran, rivaroxaban, apixaban, edoxaban, atrial fibrillation, stroke prevention  
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Introduction 
The vitamin K antagonists (VKA, e.g. warfarin) were traditionally the only available oral anticoagulants (OAC) for 
stroke prevention in patients with nonvalvular atrial fibrillation (NVAF), but more recently three non-VKA oral 
anticoagulants (NOACs), dabigatran, rivaroxaban and apixaban have become licensed for stroke prevention in AF, 
with a fourth, edoxaban, on the horizon, subject to regulatory approval. 1 2 3 4  
Treatment guidelines have evolved to reflect the availability of NOACs.  The European Society of Cardiology (ESC) 
5 and National Institute for Health and Care Excellence guidelines (NICE) 6 recommend a simple 2-step approach: 
first, to initially focus on the identification of low risk patients (essentially CHA2DS2-VASc score [Congestive heart 
failure, Hypertension, Age ≥ 75 years {double}, Diabetes mellitus, previous thromboembolism {double}, Vascular 
disease, Age 65–74 years, and female gender] =0 if male, 1 if female) who do not need any antithrombotic 
therapy; step 2 is to offer OAC to all other AF patients with ≥1 additional stroke risk factors, whether as a NOAC or 
well controlled VKA.      
In Japan, the Japanese Circulation Society (JCS) guidelines have focused on using the older CHADS2 score 
(Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, and previous stroke/transient ischemic 
attack [double]), and do not operationalize a stepwise approach to OAC management decisions. The JCS 
guidelines recommend OAC in high-risk patients with a CHADS2 score ≥2; ‘prefer’ the use of dabigatran or 
apixaban for those at intermediate-risk (CHADS2 score=1); and for ‘other risk factors’ (age 65-74, cardiomyopathy, 
vascular disease)’ OAC may be considered 7 . 
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The net clinical benefit (NCB) of OACs has been studied in ‘real world’ populations in Western countries, where a 
positive net clinical benefit, balancing stroke against serious bleeding, is evident for patients with a CHA2DS2-VASc 
score of ≥1. 8,9 Modelling NOAC data use provides evidence of even greater NCB. 10 There are currently no data on 
the potential impact on stroke reduction in Japan by using a CHA2DS2-VASc score management approach (as 
opposed to the CHADS2 score used within the JCS guidelines) to aid OAC-decision making.   
Given the benefit of OACs even in patients with ≥ 1 stroke risk factors, we performed a modeling analysis to 
investigate stroke events associated with the different OACs and compared the approach to stroke risk 
stratification based on the 2014 JCS guidelines approach (based on the CHADS2 score) and the ESC guidelines 
approach (based on CHA2DS2-VASc score), using event rates from a previously published cohort of non-
anticoagulated Japanese patients with NVAF 11.  The focus of the modeling analysis is to highlight the missed 
opportunities for stroke prevention with OACs by using the CHADS2 score instead of the CHA2DS2-VASc score, 
with reference to the 2014 JCS guideline as an illustrative example. 
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Methods  
Our modeling approach is summarized in Figure 1.  The ‘base case’ study population used for our model was 
published data11 regarding all patients with NVAF who did not receive OAC therapy during the study period from 
1995 to 2008.  Detailed medical history, including pharmacotherapy, and baseline risk stratification scores for 
ischaemic stroke/thromboembolism (IS/TE) based on the CHADS2 
12,13 and CHA2DS2-VASc 
14 scores, were available 
for all patients.   
Model assumptions 
The event rates per 100 person years for IS/TE (Table 1) were calculated using data from the published paper by 
Komatsu et al.11 for patients on no treatment, stratified by stroke risk as predicted by the CHADS2 
13 and CHA2DS2-
VASc scores. 14 These data were compared with the studies of Siu et al. 15, Guo et al. 16 and Lip et al. 14   
In the study by Siu et al. 15, a total of 10,195 Chinese patients with a diagnosis of AF were identified from a 
computer- based hospital clinical management system. Patients were excluded if they had significant valvular 
heart disease including previous valvular surgery, valvular disease with planned surgical correction, and any 
degree of mitral stenosis, or incomplete clinical and/or follow-up data. 
In the study by Guo et al. 16, patients with AF admitted to the PLA General Hospital were eligible for this study. 
Inclusion criteria were a pre-existing diagnosis of permanent, persistent, or paroxysmal AF, development of new-
onset AF during their current admission (defined on having an ECG or Holter recording). 
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In the study by Lip et al. 14, detailed survey methods, center participation, patient characteristics, management 
and definitions of the baseline and follow-up survey of the Euro Heart Survey on AF have previously been 
described. 17 18 In summary, 5,333 ambulant and hospitalized patients with AF were enrolled from the cardiology 
practices of 182 hospitals in 35 European countries. Patients were enrolled if they were ≥ 18 years old and if they 
had an ECG or Holter recording showing AF during the qualifying admission/consultation or in the preceding 12 
months. 
By using data from Komatsu et al.11, the estimated event rates and the number of IS/TE events were estimated 
for a hypothetical Japanese AF population of n=100,000 (Table 2).  Using data from recent trials of the NOACs, the 
potentially preventable stroke events were calculated in this population (Table 3).  
For this model, the relative risks of IS/TE with the NOACs compared to warfarin were assumed to be 0.65 for 
dabigatran 150 mg bid 1, 0.90 for dabigatran 110 mg bid 1, 0.88 for rivaroxaban (intention-to-treat [ITT] analysis) 2, 
0.79 for apixaban 3, 0.87 for edoxaban 60mg (ITT analysis) 4 and 1.13 for edoxaban 30mg (ITT analysis). 4  
The relative risks of IS/TE were assumed to be constant across all categories of stroke risk. On the basis of the 
general prevalence of AF in the Japanese (0.56%) in 2003 19, we estimated that a population prevalence of AF in 
Japan for 2014 to be 0.7% (n=889,000), given that the prevalence of AF in Japan might be increased in its ageing 
society. The total population of Japan was assumed about 127,000,000 based on the recent world population 
review. 20 In the paper of Komatsu et al.9, the overall observed stroke rate was 2.1%/year. Using these estimated 
figures, we modeled the potential stroke events in the total AF population for the whole of Japan, and we 
compared the impact of the JCS approach to stroke prevention in AF, with the simple CHA2DS2-VASc based 2-step 
decision making strategy advocated by the ESC and NICE guidelines.  
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Results 
Table 1 shows the event rates for IS in Siu et al. 15 and Guo et al. 16, and IS/TE in Komatsu et al. 11 and Lip et al. 14 
per 100 person years based on CHA2DS2-VASc and CHADS2 scores, which show broad comparability between 
these different populations for a given risk score value. Assuming that the Japanese AF population numbers 
100,000, the estimated number of IS/TE events on no treatment was calculated by using the event rates of IS/TE 
based on Komatsu study (Table 2).  
Whilst on warfarin, the risk reduction (RR) of overall event rates is 0.36 (95% confidential interval [CI]; 0.26-0.51) 
from no treatment, saving 64% of IS/TE events (1320.5/2063.3) by using CHA2DS2-VASc score, while saving 53.2% 
(1236.3/2321.5) by using the CHADS2 score (Table 3).  
In our model, the risk reduction of IS/TE events in all of the NOACs are compared with warfarin, with dabigatran 
150 mg bid (twice daily) having the highest reduction of 76.6% (1580.5/2063.3) compared to no treatment, and 
74.2% (1721.9/2321.5) by using CHADS2 score.  
Application of treatment guidelines based on the CHA2DS2-VASc score and the ESC/NICE management decision 
approach, stroke reductions would be 67.6% (1394.8/2063.3) on dabigatran 110mg bid, 68.3% (1409.6/2063.3) 
on rivaroxaban (ITT), 71.6% (1476.5/2063.3) on apixaban, 68.7% (1471.1/2063.3) on edoxaban 60mg od (once 
daily) (ITT) and 59.3% (1223.9/2063.3) on edoxaban 30mg od (ITT) compared to no treatment.  
Using treatment based on the CHADS2 score and JCS guideline approach, the reductions would be 65.5% 
(1519.7/2321.5) on dabigatran 110mg bid, 56.9% (1319.8/2321.5) on rivaroxaban, 69.3% (1608.6/2321.5) on 
apixaban, 57.2% (1326.7/2321.5) on edoxaban 60mg od and 49.4% (1145.9/2321.5) on edoxaban 30mg od from 
no treatment, respectively. 
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We modeled these figures to potential stroke events among total AF population in Japan (n=889000) by using 
CHA2DS2-VASc score and CHADS2 scores as follows: 4369 and 4817 for dabigatran 150mg bid, 6049 and 6448 for 
dabigatran 110mg bid, 5918 and 8056 for rivaroxaban (intention-to-treat; ITT), 5302 and 5731 for apixaban, 5843 
and 8000 for edoxaban 60mg od (ITT), 7598 and 9454 for edoxaban 30mg od (ITT), respectively.   
In every case, whether using warfarin or NOACs, prescribing OAC treatment based on the CHA2DS2-VASc score 
and the ESC/NICE management decision approach was modelled to have a numerically greater benefit for stroke 
prevention, as shown in Figure 2.     
Discussion 
In this analysis, we present a modelling analysis showing that when consider antithrombotic treatment for 
Japanese AF patients, using a CHA2DS2-VASc-based approach advocated by the European and NICE guidelines 
would allow greater opportunities for stroke prevention (especially with the NOACs).  Many international 
guidelines (eg ACCP, Canadian, etc) are still based the older CHADS2 score, and our paper – whilst focused on the 
2014 JCS guidelines - provides important learning points on missed opportunities for stroke prevention that 
would be generalizable to clinical practice outwith Japan. 
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In the 2014 JCS guidelines7, the CHADS2 score is recommended to evaluate whether patients with nonvalvular AF 
have stroke risk, and all NOACs and warfarin are recommended for patients with at least 2 risk factors (if the 
same indication, NOACs are preferable). Dabigatran and apixaban are recommended for patients with one risk 
factor (ie CHADS2 score=1), given the evidence in their respective trials; indeed, Banerjee et al 
10 concluded that 
NOACs (dabigatran, apixaban) have a positive net clinical benefits in patients with a CHA2DS2-VASc score=1 at 
high risk of bleeding and stroke, and these drugs were shown to be superior (150mg bid dabigatran, apixaban) to 
warfarin in the prevention of stroke and have a lower risk of intracranial haemorrhage (ICH) than warfarin. On the 
other hand, rivaroxaban and edoxaban can be considered for those patients since the effect and safety of 
rivaroxaban and edoxaban were evaluated in those trials only in patients with CHADS2 score of ≥ 2. In patients 
with a CHADS2 score of 0, no treatment is recommended in the JCS guidelines, but all OACs may be considered 
when patients have at least one of other risk factors (cardiomyopathy, 65 to 74 years of age, vascular disease). 
Why does the JCS guideline use the CHADS2 score for risk stratification in AF patients, and not use CHA2DS2-VASc 
score?  In a recent Editorial, the CHA2DS2-VASc score was considered ‘more complicated’ than CHADS2 score for 
Japanese clinicians 21. Nonetheless, risk stratification based on CHADS2 score itself might not be even widespread 
in clinical practice in Japan. Also, all clinical trials of NOACs were based on the CHADS2 score. In the JCS guideline 
7, the non-CHADS2 risk factors of ‘Cardiomyopathy’, ‘Age of 65 to 74 years’ and ‘vascular disease’ are defined as 
‘other risk factors’. These risk factors are essentially the ‘A’ and ‘V’ criteria of the CHA2DS2-VASc score, and 
cardiomyopathy is included within the ‘C’ criteria of CHA2DS2-VASc. However, OAC is only ‘treatment to be 
considered’ rather than being fully recommended.   
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Therefore, this modeling analysis could provide us with more useful information on the optimal approach to 
stroke in Japanese AF patients. Indeed, CHA2DS2-VASc score may be more simpler for clinicians in stroke 
prevention for Japanese AF patients, and this score is already currently recommended in the other guidelines, 
ESC 5, Asia Pacific Heart Rhythm Society (APHRS) guidelines 22, American Heart Association/American College of 
Cardiology (AHA/ACC) 23 and National Institute for Health and Care Excellence (NICE) 6.     
What do current international guidelines say?  Table 4 summarises several guidelines for antithrombotic therapy 
in NVAF, that is, the ESC 2012 5, APHRS 2013 22 , AHA/ACC/HRS 2014 23 , NICE 2014 6 , JCS 2014 7 and Canadian 
Cardiovascular Society [CCS] 2014 24 .  The ESC guidelines5 recommend the use of the CHA2DS2-VASc score in the 
assessment of all patients. In patients with a CHA2DS2-VASc score ≥2, OAC therapy with adjusted-dose VKA (INR 
2-3), dabigatran, rivaroxaban or apixaban is recommended. In male patients with a CHA2DS2-VASc score of 1, OAC 
therapy with adjusted-dose VKA (INR 2-3), dabigatran, rivaroxaban or apixaban should be considered based on an 
assessment of the risk of bleeding complications and patient preferences. However, this guideline recommends 
no antithrombotic therapy for ‘low risk’ patients <65 years and without any risk factors (including females ie. 
CHA2DS2-VASc score of 0 (males) or 1 (females) since the absolute risk of stroke is low in this population. 
25   
In the APHRS 2013 statement 22, patients are classified into 3 groups (patients with a CHA2DS2-VASc score of ≥2, 1, 
and 0). Patients with a CHA2DS2-VASc score of ≥2 should receive OAC (dabigatran, rivaroxaban, apixaban or 
warfarin), those with a score of 1 should preferentially receive NOACs (dabigatran or apixaban), and those with a 
score of 0 should receive no treatment. Rivaroxaban can be considered an alternative in patients with a score of 1 
since the effect and safety of rivaroxaban were evaluated in the ROCKET AF trial only in patients with CHADS2 
score of ≥2. Similar to the ESC 2012 guideline, female patients with sex alone as a single risk factor (still a 
CHA2DS2-VASc score of 1) are low risk should be regarded as those with a score of 0. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 12 
In the 2014 AHA/ACC/HRS guidelines 23, the CHA2DS2-VASc score is recommended for assessment of stroke risk. 
For patients with prior stroke/TIA or CHA2DS2-VASc score of 2 or greater, oral anticoagulants, warfarin (INR 2.0-
3.0), dabigatran, rivaroxaban, or apixaban, are recommended. For patients with a CHA2DS2-VASc score of 1, no 
antithrombotic therapy or treatment with an oral anticoagulant or aspirin may be considered. For patients with a 
CHA2DS2-VASc score of 0, it is reasonable to omit antithrombotic therapy.  
The 2014 NICE guidelines 6 have also shifted towards initially identifying truly low risk patients who will not 
benefit from antithrombotic therapy (that is CHA2DS2-VASc score=0 for men or score= 1 for females), as the first 
decision step.  Subsequent to this step, oral anticoagulation can be offered to patients with ≥1 additional stroke 
risk factors, taking bleeding into account. In contrast to other expert-consensus guidelines, the NICE guidelines 
are based on systematic reviews, evidence appraisal and cost effectiveness, with a multidisciplinary guideline 
development group that includes patient representatives. 
The CCS Guidelines 2014 24 recommends that OAC therapy be prescribed for most patients aged ≥ 65 years or 
CHADS2 score ≥ 1. ASA (81 mg/d) can be prescribed for patients with age<65 years and no CHADS2 risk factors 
who have arterial disease (coronary, aortic, or peripheral). No antithrombotic therapy should be recommended 
for patients with age < 65 and no CHADS2 risk factors and free of arterial vascular disease. Similar to the JCS 
guideline, the CCS guideline 2014 also recommended use of the CHADS2 score for stroke risk stratification.   
However, a recent analysis26 shows that the ‘OAC not recommended’ subgroup based on the 2014 CCS guideline, 
can still have a high 1 year stroke rate overall (>4%/year) if untreated, showing that such patients are not ‘low 
risk’.  
In the present modeling analysis using the 2014 JCS guideline as an illustrative example, we report the current 
situation of using the CHADS2 score and highlight the missed opportunities for stroke prevention by using the 
CHADS2 score instead of the CHA2DS2-VASc score.   
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In the JCS guidelines, warfarin can be considered for stroke prevention in patients with CHADS2 score=1, or 
‘CHADS2 score =0 and other risk factors’, because it is unclear whether the benefit of stroke prevention 
overweighs the risk of bleeding in such these patients. Also, when warfarin is administered, it is recommended 
that a target internationalized normalized ratio (INR) of 2.0 to 3.0 be set in patients <70 years, whilst patients 
age >70 years should be maintained with an INR 1.6 to 2.6, since some Japanese data suggest that an INR less 
than 1.6 increases the incidence of serious cerebral infarction and an INR above 2.6 increases serious bleeding 
complications. 27 28   An INR of 2.6-2.99 is also effective, but associated with a slightly increased risk in major 
haemorrhage. 29    
This target INR range in elderly Japanese is different to other non-Japanese studies, where bleeding risk starts to 
rise only from INRs >3.0 and at INRs <3.0, the risk is low and constant, rather than declining further.  Indeed, 
many presentations of bleed events occur even when patients are within a therapeutic range of 2.0-3.0, and we 
recognize that it is the quality of INR control, as reflected by the average individual time in therapeutic range (TTR) 
is the more important parameter30 31.  Published studies from Asian population generally indicate a low TTR in 
these studies 32 33 34 35. 
When Asian and non-Asian patients receiving warfarin are compared, the risks of ischemic stroke, hemorrhagic 
stroke and major bleeding were twice higher in Asian than in non-Asian patients36. It is possible that a racial or 
genetic factor is involved in this difference, which has been pointed out for years, but we should also consider 
other factors because no such differences were observed in a comparison between Asian and non-Asian patients 
receiving dabigatran. In the Randomized Evaluation of Long-term Anticoagulation Therapy (RELY) substudy, the 
low average INR value and the low TTR in Asian patients may be the biggest reasons for the higher risks of 
ischemic stroke and hemorrhagic stroke. The sub-analysis of the RE-LY trial 1 revealed that the percentage of 
patients with a mean INR of 2 to 3 was 68.9% and 56.5% in non-Asian and Asian patients, respectively. In the 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 14 
same way, the percentage of patients with a mean INR of 2 to 3 was 55.2% and 52.4% in overall patients and 
Asian patients in Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism 
for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET) trial 2, 67% and 60% in non-Asian and 
Asian patients in Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation 
(ARISTOTLE) trial 3, respectively.  
Thus, these results suggest that Asian patients are not receiving optimally managed warfarin therapy. Additionally, 
TTR was generally lower in Asian countries compared to non-Asians 36. Physicians in Japan should be encouraged 
to maintain TTR at an appropriate level (≥70%) even when elderly patients receive warfarin therapy. If so, 
warfarin can be prescribed for patients with a CHA2DS2-VASc score of ≥1 in Japanese population as described in 
the guidelines 22.  Indeed, guideline-adherent therapy is associated with much better outcomes in AF patients 37 
38.     
Limitations  
Whilst Komatsu et al paper11 does reflect an everyday clinical practice observational cohort setting, this does not 
hold true for the randomised trials, and therefore, modeling the expected benefit of NOACs on the basis of trial 
outcomes may not be the same as if derived from a clinical registry of these. All the NOACs are powerful 
anticoagulants, and would work well if used correctly, and when used in the appropriate patients. We have also 
made no assumptions on quality of anticoagulation control with warfarin (as measured by the time in therapeutic 
range), which may be fairly variable in the cohorts and related to prognosis 39 40. Residual confounding may also 
be possible given the current comprehensive approach to stroke risk reduction in AF populations 41. Second, 
although the numbers of patients were relatively small, the study period was long (mean 53 months), and the 
distribution of study patients showed broad comparability between these different populations for a given risk 
score value as described in Table 2. Therefore, in the absence of better published data, we decided that the study 
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by Komatsu et al. was reasonable enough to use for this modeling analysis.  Moreover, according to a report from 
the J-RHYTHM registry, anticoagulant therapy is administered in more than 80% of patients with nonvalvular AF. 
42 Therefore, it would be very difficult to find other contemporary data to model the natural incidence of ischemic 
stroke/systemic embolism in untreated Japanese patients with AF based on current clinical practice. 
Third, the JCS guidelines recommends physician to prevent stroke by combination of CHADS2 score and some 
consideration of ‘other risk factors’ (ie. cardiomyopathy, age 65-74 and vascular disease), and not soley on the 
CHADS2 score per se. Therefore, stroke prophylaxis by using only CHADS2 score, which is calculated in this 
modeling study, does not fully reflect the JCS guidelines. Fourth, female gender is not considered as independent 
risk factor for the incidence of stroke in Japanese NVAF patients, although the analysis was based in a largely 
anticoagulated registry cohort43.  In contrast, female gender is an independent predictor for stroke in Chinese 
patients with nonvalvular AF and CHA2DS2-VASc score of ≤1 (HR: 2.3, 95% CI: 1.1–4.8) 
44 . Moreover, Ogawa et al. 
recommended use of CHA2DS2-VASc score in stroke prevention in the 2013 APHRS statement
22.  Hence, further 
research is needed to explore the influence of female gender on the incidence of stroke, amongst Japanese 
patients. 
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Whilst the debate on whether using CHADS2 score and other risk factors or simply using CHA2DS2-VASc score 
continues, both scoring systems have advantages and disadvantages45.  However, we believe that the use of 
CHA2DS2-VASc score could make stroke prevention simple and consequently lead to the intial identification of 
“truly” low risk patients as a first step, following which effective stroke prevention can be offered to those with ≥1 
additional stroke risk factors.   Finally, we did not analyze the bleeding risk on antithrombotic therapy because 
there are no published Japanese papers regarding bleeding rates based on CHA2DS2-VASc score and HAS-BLED 
score (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile 
international normalized ratio, Elderly (> 65 years), Drugs/alcohol concomitantly)46. Indeed, modeling the 
expected net clinical benefit of OACs would be informative in further studies of Japanese AF patients.    
In conclusion, our modelling analysis has shown that when considering antithrombotic treatment for Japanese AF 
patients, using a CHA2DS2-VASc-based approach would allow greater opportunities for stroke prevention. 
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Figure legends 
 
Figure 1: 
Flow chart of modelling procedure 
 
Figure 2: 
Annual Estimated stroke events among all Japanese AF population (n=889,000) according to CHADS2 and 
CHA2DS2-VASc scores 
 
AF; atrial fibrillation, CHADS2 score; Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, and 
previous stroke/transient ischemic attack (double), CHA2DS2-VASc score; Congestive heart failure, Hypertension, 
Age ≥ 75 years (double), Diabetes mellitus, previous thromboembolism (double), Vascular disease, Age 65–74 
years, and female gender, ITT; intention-to-treat 
* calculated by observed annual stroke rate (2.1%/year) 11) 
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Table 1 Ischaemic stroke rate without oral anticoagulants based on the CHA2DS2-VASc and CHADS2 scores   
 
 
*rate of ischaemic stroke and systemic thromboembolism † no 95% CI stated in the article 
CHA2DS2-VASc score; Congestive heart failure, Hypertension, Age ≥ 75 years (double), Diabetes 
mellitus, previous thromboembolism (double), Vascular disease, Age 65–74 years, and female 
gender  
CHADS2 score; Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, and 
previous stroke/transient ischemic attack (double).  CI; confidential interval  
 
Komatsu et 
al.*11) 
Siu et 
al.15) 
 Guo et al.16)  Lip et al.*14) 
 n=332 n=3881  n=885  n=1084 
CHA2DS2-
VASc 
score 
Annual rates 
(%/year;95% 
CI) 
Annual 
rates 
(%/year) 
CHA2DS2-
VASc score 
Annual rates 
(%/year;95% CI) 
CHA2DS
2-VASc 
score 
Annual rates 
(%/year;95% CI) 
0 0 2.41 0-1  0 0 
1 
0.6 
(0.45-0.76) 
6.64 Male 
0.45 
(0.01-2.50) 
1 
0.6 
(0-3.4) 
2 
0.95 
(0.73-1.18) 
7.84 Female 
1.59 
(0.04-8.53) 
2 
1.6 
(0.3-4.7) 
3 
1.96 
(1.65-2.28) 
9.56 ≥2  3 
3.9 
(1.7-7.6) 
4 
5.45 
(5.06-5.85) 
11.58 Male 
2.87 
(1.95-4.07) 
4 
1.9 
(0.5-4.9) 
5 
9.06 
(8.41-9.72) 
12.69 Female 
2.59 
(1.35-4.48) 
5 
3.2 
(0.7-9.0) 
≥6 
13.7 
(11.79-15.62) 
13.18   6 
3.6 
(0.4-12.3) 
     7 
8.0 
(1.0-26.0) 
     8 
11.1 
(0.3-48.3) 
     9 
100 
(2.5-100) 
       
CHADS2 
score 
  
CHADS2 
score 
 
CHADS2 
score† 
 
0 
0.21 
(0.10-0.33) 
5.44 0-1  0 1.4 
1 
0.93 
(0.79-1.07) 
8.59 Male 
1.18 
(0.38-2.73) 
1 1.9 
2 
2.78 
(2.61-2.96) 
11.24 Female 
1.83 
(0.50-4.63) 
≥2 3.1 
3 
9.41 
(8.98-9.85) 
11.86 ≥2    
≥4 
10.92 
(10.18-11.67) 
14.06 Male 
3.09 
(2.03-4.49) 
  
   Female 
2.91 
(1.34-5.46) 
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Table 2 
Modelling event rates in a hypothetical Japanese AF population with no treatment (n=100,000) 
 
Komatsu et 
al.11) 
(n=332) 
 
Hypothetical 
Japanese AF 
population 
(n=100,000) 
 
 
Number of 
patients (n=; %) 
Annual rates 
(%/year; 95% CI) 
Estimated  
Number of 
patients (n=) 
Estimated 
number of stroke 
events  
(n=; 95% CI) 
CHA2DS2-VASc score     
0 76(23) 0 23000 0 
1 60(18) 
0.6  
(0.45-0.76) 
18000 
108 
(81-136.8) 
2 69(21) 
0.95 
(0.73-1.18) 
21000 
199.5 
(153.3-247.8) 
3 69(21) 
1.96 
(1.65-2.28) 
21000 
411.6 
(346.5-478.8) 
4 28(8) 
5.45 
(5.06-5.85) 
8000 
436 
(404.8-468) 
5 23(7) 
9.06 
(8.41-9.72) 
7000 
634.2 
(588.7-680.4) 
≥6 7(2) 
13.7 
(11.79-15.62) 
2000 
274 
(235.8-312.4) 
     
CHADS2 score     
0 115(35) 
0.21 
(0.10-0.33) 
35000 
73.5 
(35-115.5) 
1 114(34) 
0.93 
(0.79-1.07) 
34000 
316.2 
(268.6-363.8) 
2 53(16) 
2.78 
(2.61-2.96) 
16000 
444.8 
(417.6-473.6) 
3 30(10) 
9.41 
(8.98-9.85) 
10000 
941 
(898-985) 
≥4 20(5) 
10.92 
(10.18-11.67) 
5000 
546 
(509-583.5) 
 
AF; Atrial fibrillation, CI; confidential interval, CHA2DS2-VASc score; Congestive heart failure, 
Hypertension, Age ≥ 75 years (double), Diabetes mellitus, previous thromboembolism (double), 
Vascular disease, Age 65–74 years, and female gender, CHADS2 score; Congestive heart failure, 
Hypertension, Age ≥ 75 years, Diabetes mellitus, and previous stroke/transient ischemic attack 
(double)  
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Table 3  
Estimated strokes on no treatment, warfarin and NOACs in a hypothetical Japanese AF population (n=100,000)  
 
Assuming 
Number 
of 
patients 
(n) 
No treatment 
(n) 
 
Warfarin  
(n) 
Dabigatran 
150 (n) 
Dabigatran 
110 (n) 
Rivaroxaban 
(ITT)  
(n) 
Apixaban 
(n) 
Edoxaban 60 
(ITT) (n) 
Edoxaban 30 
(ITT) (n) 
   
RR*0.36 
(CI;0.26-0.51) 
RR†0.65 
(CI;0.52-0.81) 
RR† 0.90 
(CI;0.74-1.1) 
RR† 0.88 
(CI;0.74-1.03) 
RR† 0.79 
(CI;0.66-0.95) 
RR† 0.87 
(CI;0.73-1.04) 
RR† 1.13 
(CI;0.96-1.34) 
Based on ESC/NICE guidelines 
CHA2DS2-VASc 
score 
         
Score =0 23000 0 ‡ ‡ ‡ ‡ ‡ ‡ ‡ 
Score =1 18000 
108 
(81-136.8) 
38.9§ 
(28.1-55.1) 
25.3 
(20.2-31.5) 
35.0 
(28.8-42.8) 
34.2 
(28.8-40.1) 
30.7 
(25.7-37.0) 
33.8 
(28.4-40.5) 
44.0 
(37.3-52.1) 
Score =2 21000 
199.5 
(153.3-247.8) 
71.8 
(51.9-101.7) 
46.7 
(37.3-58.2) 
64.6 
(53.1-79) 
63.2 
(53.1-74) 
56.7 
(47.4-68.2) 
62.5 
(52.4-74.7) 
81.1 
(68.9-96.2) 
Score =3 21000 
411.6 
(346.5-478.8) 
148.2 
(107-209.9) 
96.3 
(77.1-120.0) 
133.4 
(109.7-163) 
130.4 
(109.7-152.6) 
117.1 
(97.8-140.8) 
128.9 
(108.2-154.1) 
167.5 
(142.3-198.6) 
Score =4 8000 
436 
(404.8-468) 
157 
(113.4-222.4) 
102.1 
(81.6-127.2) 
141.3 
(116.2-172.7) 
138.2 
(116.2-161.7) 
124 
(103.6-149.2) 
136.6 
(114.6-163.3) 
177.4 
(150.7-210.4) 
Score =5 7000 
634.2 
(588.7-680.4) 
228.3 
(164.9-323.4) 
148.4 
(118.7-184.9) 
205.5 
(168.9-251.1) 
200.9 
(168.9-235.1) 
180.4 
(150.7-216.9) 
198.6 
(166.7-237.4) 
258.0 
(219.2-305.9) 
Score ≥6 2000 
274 
(235.8-312.4) 
98.6 
(71.2-139.7) 
64.1 
(51.3-79.9) 
88.7 
(73.0-108.5) 
86.8 
(73.0-101.6) 
77.9 
(65.1-93.7) 
85.8 
(72-102.5) 
111.4 
(94.7-132.1) 
 
100000 
 
2063.3 
(1810-2324.2) 
 
742.8 
(536.5-
1052.3) 
 
 
482.8 
(386.3-601.7) 
 
 
668.5 
(549.7-817.1) 
 
 
653.7 
(549.7-765.1) 
 
 
586.8 
(490.2-705.7) 
 
 
646.2 
(542.2-772.5) 
 
 
839.4 
(713.1-995.4) 
 
 
Potentially 
preventable 
stroke events 
  -1320.5 -1580.5 -1394.8 -1409.6 -1476.5 -1417.1 -1223.9 
Additional 
strokes 
prevented vs 
warfarin 
   -260 -74.3 -89.1 -156 -96.6 +96.6 
Based on JCS guideline ¶ 
CHADS2 score          
Score =0 35000 73.5 ‡ ‡ ‡ ‡ ‡ ‡ ‡ 
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(35-115.5) 
Score =1 34000 
316.2 
(268.6-363.8) 
|| 
74 
(59.2-92.2) 
102.4 
(84.2-125.2) 
|| 
89.9 
(75.1-108.1) 
|| || 
Score =2 16000 
444.8 
(417.6-473.6) 
160.1 
(116.7-226.8) 
104.1 
(83.3-129.7) 
144.1 
(118.5-176.1) 
140.9 
(118.5-164.9) 
126.5 
(105.7-152.1) 
139.3 
(116.9-166.5) 
180.9 
(153.7-214.5) 
Score =3 10000 
941 
(898-985) 
338.8 
(244.7-479.9) 
220.2 
(176.2-274.4) 
304.9 
(250.7-372.7) 
298.1 
(250.7-349.0) 
267.7 
(223.6-321.9) 
294.8 
(247.3-352.4) 
 
382.8 
(325.2-454.0) 
Score ≥4 5000 
546 
(509-583.5) 
196.6 
(142.0-278.5) 
127.8 
(102.2-159.2) 
176.9 
(145.5-216.3) 
173.0 
(145.5-202.5) 
155.3 
(129.8-186.8) 
171.0 
(143.5-204.5) 
222.2 
(188.7-263.4) 
 100000 
2321.5 
(2128-2521.4) 
1085.2 
(807-1464.5) 
 
599.6 
(455.9-771) 
 
801.8 
(633.9-1005.8) 
 
1001.7 
(818.3-1195.6) 
 
712.9 
(569.2-884.4) 
 
994.8 
(811.3-1202.7) 
 
1175.6 
(971.2-1411.2) 
 
Potentially 
preventable 
stroke events 
  -1236.3 -1721.9 -1519.7 -1319.8 -1608.6 -1326.7 -1145.9 
Additional 
strokes 
prevented vs 
warfarin 
   -485.6 -283.4 -83.5 -372.3 -90.4 +90.4 
 
NOAC; Non-VKA oral anticoagulants  
AF; atrial fibrillation 
ITT; Intention-to-treat analysis 
CHA2DS2-VASc score; Congestive heart failure, Hypertension, Age ≥ 75 years (double), Diabetes mellitus, previous 
thromboembolism (double), Vascular disease, Age   65–74 years, and female gender 
CHADS2 score; Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, and previous 
stroke/transient ischemic attack (double) 
RR; risk ratio 
*versus No treatment  
†versus Warfarin  
‡not recommended    
§ warfarin can be alternative option 
|| can be considered 
¶ no consideration in regards to other risk factors (Cardiomyopathy, 65 to 74 years of age, or vascular disease 
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Table 4: Summary of recommendations proposed by several guidelines  
 
Based on CHADS2 score 
 CHADS2≥2 CHADS2=1 CHADS2=0 
JCS 2014 7) 
  
Other risk 
factorsa 
No risk factor 
D/R/A/E/ 
Wb 
 
D/A 
(R/E/Wb can be 
considered) 
(D/R/A/E/Wb 
can be 
considered) 
No Tx 
 
CCS 2014 24) OACc 
Age 65-74 
Vascular 
disease 
No risk 
factor 
OACc Aspirin No Tx 
Based on CHAD2DS2-VASc 
 
CHAD2DS2-
VASc≥2 
CHAD2DS2-VASc=1 CHAD2DS2-VASc=0 
ESC 2012 5) 
NOAC 
No TX 
Wafarin (alternative) 
 
APHRS2013 22) OAC (D/R/A/W) 
NOAC (D/A) 
W/R (alternative) 
No Tx 
 
ACC/AHA/HRS 2014 
23) 
OAC (D/R/A/W) 
(class I) 
OAC (D/R/A/W) or No Tx 
or Aspirin (can be 
considered) 
(class IIb) 
No Tx 
(class IIa) 
 
NICE 2014 6) OAC (D/R/A/W) 
Women: No Tx 
No Tx Men: OAC (D/R/A/W) 
(can be considered) 
 
JCS, Japanese Circulation Society; CCS,  Canadian Cardiovascular Society; ESC, European Society of 
Cardiology; APHRS, Asia Pacific Heart Rhythm Society; ACC/AHA/HRS, American Heart 
Association/American College of Cardiology/ Heart Rhythm Society; NICE, National Institute for 
Health and Care Excellence; CHA2DS2-VASc score, Congestive heart failure, Hypertension, Age ≥ 75 
years (double), Diabetes mellitus, previous thromboembolism (double), Vascular disease, Age 65–74 
years, and female gender; CHADS2 score, Congestive heart failure, Hypertension, Age ≥ 75 years, 
Diabetes mellitus, and previous stroke/transient ischemic attack (double); OAC, oral anticoagulation; 
NOAC, non-VKA oral anticoagulants;  
D, dabigatran; R, rivaroxaban; A, apixaban; E, edoxaban; W, warfarin 
a; Cardiomyopathy, 65 to 74 years of age, or vascular disease. 
b;  age<70  INR 2.0-3.0,  age≥70 INR 1.6-2.6 
c: NOACs (D, R, A) > warfarin 
 
 
 
